Skip to main content
    J

    Jazz Pharmaceuticals PLC (JAZZ)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $239.77
    -1.78 (-0.74%)

    Market Cap: $15.50B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Jazz Pharmaceuticals PLC (JAZZ) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Jazz Pharmaceuticals (JAZZ) trades at 18.4x trailing earnings and 3.3x sales. Its P/E of 18.4x is above its 5-year median of 9.5x. Its forward P/E is 10.3x. The median P/E across 4 similar companies is 18.5x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 78.6% higher over the next year. Its free cash flow yield is 4.6%.

    MultipleValue
    P/E (trailing)18.4x
    Forward P/E10.3x
    Price to sales3.3x
    Price to book3.7x
    EV/EBITDA16.6x
    Price to FCF21.7x
    EV/FCF26.7x
    PEG1.0
    FCF yield4.6%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 84.0% above 10.0x, its P/S is 13.8% above 2.9x and its P/B is 42.3% above 2.6x.

    MultipleCurrent5-year median10-year median
    P/E18.4x9.5x10.0x
    P/S3.3x2.3x2.9x
    P/B3.7x2.3x2.6x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 5.8x in 2024 to 24.1x in 2025. 2025 was the highest of those years.

    Year endPriceP/EP/SP/B
    2025$170.0024.1x2.4x2.4x
    2024$123.155.8x1.9x1.9x
    2023$123.006.7x2.1x2.3x
    2022$159.3112.1x2.7x3.3x
    2021$127.407.8x2.5x2.0x
    2020$165.0513.2x3.9x2.6x
    2019$149.289.2x3.9x2.7x
    2018$123.969.1x3.9x2.7x
    2017$134.6512.2x5.0x3.0x
    2016$109.0310.7x4.5x3.5x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About JAZZ

    What is JAZZ's forward P/E ratio?

    Jazz Pharmaceuticals has a forward P/E ratio of 10.3x.

    Is JAZZ stock overvalued?

    GNG's valuation label for JAZZ is Fairly valued. Its P/E of 18.4x compares with a median of 18.5x across 4 similar companies.

    What is JAZZ's price to sales ratio?

    Jazz Pharmaceuticals has a price to sales ratio of 3.3x.

    What is Jazz Pharmaceuticals's average P/E ratio over 5 years?

    Jazz Pharmaceuticals's median P/E over the last 5 years is 9.5x, from 60 month-end values through Oct 2026.

    What is JAZZ's PEG ratio?

    Jazz Pharmaceuticals has a PEG ratio of 1.0.